https://www.selleckchem.com/pr....oducts/lomerizine-hc
The Network of practices had more bone metastases, and breast, cervical, and uterine cancers but less lung and prostate cancer than the RO-APM dataset. Combination-modality episodes were more costly and required more providers than single-modality episodes. Clinical Rules reattributed 2,495 episodes (3.4%) and increased episode reimbursement by +5.8% over all disease sites (+3.7% using volume weighting; P = .001). CONCLUSION As payment models continue to shift from volume to value, practices will need an automated analytics techn
Like
Comment
Share
